Biohit Oyj Press Release April 8, 2015 at 9:30 a.m. local time (EEST)
The accurate and easy-to-use Biohit Quick Test Reader allows effective use of Biohit ColonView Quick Test and Biohit Celiac Disease Quick Test in point-of-care setting. Quick test reader is especially suitable for mobile units due to its robust construction and non-dependency on electric current (rechargeable batteries). The reader has a data storing capacity on a memory card, and it is compliant with most hospital and laboratory information systems (HIS/LIS).
Biohit ColonView Quick Test is the best colorectal cancer screening tool on the market and the new instrument enables screenings. A hospital-derived cohort of 300 subjects were tested using the new-generation Biohit ColonView fecal immunochemical Test (FIT) and the traditional test for fecal occult blood (FOB). The results indicate that ColonView was superior to the conventional FOB test in colorectal cancer screening due to its significantly higher sensitivity. ColonView quick test detects both hemoglobin (Hb) and hemoglobin-haptoglobin (Hb/Hp) complex.
The Celiac Quick test is an immunochromatographic test designed for the qualitative detection of antibodies (IgA/IgG/IgM) against human tissue transglutaminase in whole blood sample.
The celiac disease quick test allows the diagnosis of celiac disease from fingertip blood sample. Celiac disease is a relatively common autoimmune disease in which the rye, wheat and barley protein (gluten) causes inflammation and mucosal damage of the small intestine, which interferes with the absorption of nutrients.
CEO Semi Korpela, Biohit Oyj: ‘This robust portable instrument is suitable for various settings including both fixed and mobile laboratories. Together with the state-of-the-art Biohit Quick Tests, the instrument enables effortless diagnostic accuracy.’
Additional information:
CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861
investor.relations@biohit.fi
www.biohithealthcare.com
Biohit in brief
Biohit Oyj is a globally operating Finnish biotechnology company. Biohit’s mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit's Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com